[go: up one dir, main page]

MX2017009154A - Sintesis de un inhibidor de tirosina quinasa de bruton. - Google Patents

Sintesis de un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2017009154A
MX2017009154A MX2017009154A MX2017009154A MX2017009154A MX 2017009154 A MX2017009154 A MX 2017009154A MX 2017009154 A MX2017009154 A MX 2017009154A MX 2017009154 A MX2017009154 A MX 2017009154A MX 2017009154 A MX2017009154 A MX 2017009154A
Authority
MX
Mexico
Prior art keywords
bruton
synthesis
tyrosine kinase
kinase inhibitor
inhibitor
Prior art date
Application number
MX2017009154A
Other languages
English (en)
Other versions
MX366827B (es
Inventor
Chen Wei
Goldman Erick
Benhaim Cyril
Horvath Andras
Pye Philip
S Smyth Mark
J Verner Erik
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017009154A publication Critical patent/MX2017009154A/es
Publication of MX366827B publication Critical patent/MX366827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente memoria se describe la síntesis de inhibidor de tirosina quinasa de Bruton (Btk) de 1-((R)-3-(4-amino-3-(4-fenoxif enil)-1H-pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1- ona.
MX2017009154A 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton. MX366827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2017009154A true MX2017009154A (es) 2017-10-12
MX366827B MX366827B (es) 2019-07-25

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008815A MX394327B (es) 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton
MX2017009154A MX366827B (es) 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008815A MX394327B (es) 2015-01-14 2016-01-14 Sintesis de un inhibidor de tirosina quinasa de bruton

Country Status (16)

Country Link
US (6) US20180009814A1 (es)
EP (1) EP3245208A4 (es)
JP (2) JP2018502077A (es)
KR (1) KR20170102887A (es)
CN (2) CN107108640A (es)
AU (2) AU2016206693A1 (es)
BR (1) BR112017015206B1 (es)
CA (2) CA3210320A1 (es)
HK (1) HK1246293A1 (es)
IL (4) IL322449A (es)
MA (1) MA41350A (es)
MX (2) MX394327B (es)
RU (1) RU2017128308A (es)
SG (2) SG11201705678YA (es)
WO (1) WO2016115356A1 (es)
ZA (1) ZA201704338B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214532B2 (en) * 2015-02-12 2019-02-26 Shanghai Dude Medical Science and Technology Co., Ltd. Process for preparing ibrutinib
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
US20200369611A1 (en) * 2017-08-01 2020-11-26 Boehringer Ingelheim International Gmbh Intermediate compounds and methods
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
CN113874378A (zh) * 2019-05-21 2021-12-31 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
CN120136774A (zh) 2019-05-21 2025-06-13 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
EP2228369A1 (en) * 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
WO2016115869A1 (zh) * 2015-01-21 2016-07-28 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途

Also Published As

Publication number Publication date
AU2020230323A1 (en) 2020-10-01
MA41350A (fr) 2017-11-21
US20190367518A1 (en) 2019-12-05
MX394327B (es) 2025-03-24
EP3245208A1 (en) 2017-11-22
US20200347064A1 (en) 2020-11-05
US20220098200A1 (en) 2022-03-31
SG10201906517VA (en) 2019-08-27
US20250197404A1 (en) 2025-06-19
WO2016115356A1 (en) 2016-07-21
HK1246293A1 (zh) 2018-09-07
BR112017015206B1 (pt) 2023-04-11
US20180009814A1 (en) 2018-01-11
MX2019008815A (es) 2019-09-26
CA3210320A1 (en) 2016-07-21
IL322449A (en) 2025-09-01
JP2018502077A (ja) 2018-01-25
IL253020A0 (en) 2017-08-31
IL308276A (en) 2024-01-01
ZA201704338B (en) 2023-10-25
CN113816962A (zh) 2021-12-21
IL274716A (en) 2020-07-30
SG11201705678YA (en) 2017-08-30
JP2021035947A (ja) 2021-03-04
MX366827B (es) 2019-07-25
BR112017015206A2 (pt) 2018-06-19
US20240158400A1 (en) 2024-05-16
KR20170102887A (ko) 2017-09-12
RU2017128308A3 (es) 2019-10-24
EP3245208A4 (en) 2018-10-17
CN107108640A (zh) 2017-08-29
AU2016206693A1 (en) 2017-07-13
CA2971460C (en) 2023-10-10
CA2971460A1 (en) 2016-07-21
RU2017128308A (ru) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2017009154A (es) Sintesis de un inhibidor de tirosina quinasa de bruton.
BR112015021995A2 (pt) combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX394784B (es) Composiciones farmacéuticas de un inhibidor de tirosina cinasa de bruton.
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
HK1215374A1 (zh) 依鲁替尼联合疗法
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
HK1249737A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
HUE064539T2 (hu) Foszfodiészteráz-gátlókat tartalmazó, módosított hatóanyag-leadású tabletta formulációk
WO2016066726A3 (en) Active acrylamides
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
HK1228260A1 (en) Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
HK1260107A1 (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
HK40019173A (en) Inhibitors of bruton's tyrosine kinase
UY35800A (es) Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias

Legal Events

Date Code Title Description
FG Grant or registration